RT期刊文章SR电子T1 GAD67和其他抗原的抗体测定患者GAD65 Antibody-Associated综合症(P5.033)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P5.033 VO 82是10补充A1 Nuria Gresa-Arribas A1海伦娜Ar首页ino A1莉迪亚萨瓦特A1 Eva Caballero A1梅西Alba A1 Eugenia马丁斯A1 Mar小艾伯特A1 Saiz A1约瑟Dalmau A1弗朗西斯克格劳年2014 UL //www.ez-admanager.com/content/82/10_Supplement/P5.033.abstract AB目的:确定患者的抗体群体的GAD65 Antibody-Associated综合症。背景:高滴度抗体GAD65一直在描述各种各样的障碍,包括小脑性共济失调(CA), stiff-person综合症(SMS)和边缘脑炎/癫痫(LE)。的各种表型表明差异GAD65-antibody浓度和/或共存自身免疫可能出现在这些病人。方法:109例GAD65-antibody-associated综合症(40 CA, 32 SMS和37例)被纳入研究。GAD65-antibodies的存在被证实与鼠小脑,免疫组织化学和ELISA或细胞试验(CBA)。GAD67-antibodies测定CBA,神经细胞表面抗原的抗体与免疫荧光检查培养海马神经元和抗原CBA (NMDAR、GABAaR GABAbR, GlyR)。结果:GAD67-antibodies被确定在82/109(75%)的患者anti-GAD65综合症有关。有相关性的存在更高浓度的GAD65-antibodies和GAD67-antibodies的存在(p = 0.0054)。所有临床表型与类似的一系列GAD65-antibody滴度。在所有患者GAD65-antibodies识别线性抗原表位免疫印迹(可见的)。 Thirteen patients had co-existing cell surface antibodies: 5 GlyR, 5 GABAaR, 1 GABAb receptor, and 1 NMDA receptor. The presence of cell surface antibodies was more frequent in patients with LE (7/37, 19%) compared with patients with CA (4/40, 10%) or SMS (2/32, 6%). Conclusions: 75% of patients with GAD65-antibody-associated syndromes have GAD67-antibodies. The association of GAD67-antibodies with LE has not been previously reported. The variety of phenotypes occurring in association with GAD65-antibodies cannot be explained by differences in GAD65-antibody titers (similar range in all phenotypes) or the presence of GAD67-antibodies. In a subset of patients with LE the clinical picture is likely related to coexisting and more relevant antibodies to cell-surface antigens. Funded by FIS PI11/01780 and PI12/00611, the NIH RO1NS077851 and Fundació la Marató de TV3 (101530)Disclosure: Dr. Gresa-Arribas has nothing to disclose. Dr. Ariño has nothing to disclose. Dr. Sabater has nothing to disclose. Dr. Caballero has nothing to disclose. Dr. Alba has nothing to disclose. Dr. Martínez-Hernandez has nothing to disclose. Dr. Petit has nothing to disclose. Dr. Saiz has received personal compensation for activities with Bayer Schering, Merck Serono, Biogen Idec, Sanofi-Aventis Pharmaceuticals Inc., Teva Neuroscience, and Novartis. Dr. Dalmau has received personal compensation in an editorial capacity for Up To Date. Dr. Dalmau has received royalty payments from Athena Diagnostics. Dr. Dalmau has received research support from Euroimmun. Dr. Graus has nothing to disclose.Wednesday, April 30 2014, 3:00 pm-6:30 pm